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assumed a constant change in utility occurs with a one unit
change in BMI. However, recent studies demonstrate the magni-
tude of changes in utility scores may vary depending on: a)
whether a patient is valuing weight loss or gain; b) whether a
smaller or larger change in body weight is being evaluated; and
c) baseline BMI. CONCLUSIONS: Various utility values associ-
ated with body weight using different methodologies have been
published. Careful consideration should be given to determine
the most appropriate utility values to use in cost utility analyses
of T2DM therapies.
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OBJECTIVES: To develop a multidimensional speciﬁc question-
naire of factors related to weight loss therapies proposed for the
assessment of therapy success or failure. METHODS: Three focus
groups of patients where debriefed and an expert panel gathered
relevant issues and converted them into 54 items around 9 dimen-
sions: Alimentary Habits, Expectations towards Therapy, Effort
and Concern, Emotion, Conﬁdence, Believes, Motivation towards
Physical Exercise, Motivation towards Weight Loss, and Per-
ceived Control. Comprehension and legibility were questioned in
a pilot sample. A ﬁrst item reduction was done to avoid redun-
dancies and to establish content agreement. Item reduction was
carried out in a sample of patients using factor analysis. Feasi-
bility, reliability, content validity and factor validity were assessed.
RESULTS: A panel of 11 practitioners and researchers, belong-
ing to different health centers in the Community of Madrid gath-
ered 3 samples: One sample of 8 chronic patients participating in
3 focus groups; a sample of 8 patients to assess feasibility; a sample
of 121 patients for item reduction. A ﬁrst conceptual reduction
conveyed a 32 item version. After measurement in a representa-
tive sample a ﬁnal 17 items form was accepted. Items were
arranged around 6 dimensions: Impulsiveness, External Locus of
Control, Internal Locus of Control, Emotiveness, Motivation
towards Therapy and Exercise, and Personal Image. Overall
Cronbach’s a was 0.772 (ICC 95% conﬁdence interval =
0.698–0.835). The 6 dimensions solution accounted for 71.2%
of variance, with all eigenvalues above 1. CONCLUSIONS: The
new questionnaire is a very short inventory of factors which might
have screening properties in order to forecast the efﬁcacy of
weight loss therapies. Although further prospective research is
being carried out in order to assess predictive validity, basic psy-
chometric properties are good as a baseline model. Resulting
dimensions are meaningful and well formed.
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OBJECTIVES: To evaluate the impact of the ﬁrst selective
cannabinoid type 1 (CB1) receptor blocker, rimonabant, devel-
oped for the management of cardiometabolic risk factors, on
health related quality of life (HRQOL) in overweight/obese
patients with type 2 diabetes. METHODS: A total of 1045
patients with type 2 diabetes were randomized in a double-blind
trial and received either rimonabant 5 mg, 20 mg or placebo.
Patients completed the Impact of Weight on Quality of Life-Lite
(IWQOL-Lite), a validated 31-item questionnaire speciﬁcally
designed for HRQOL assessment in obesity, and reported days
missed from work at baseline and every 3-months up to 1 year.
Analyses were performed on mean score changes from baseline
to 1 year in the ITT population. Clinical meaningfulness was
assessed using the Effect Size (ES) method, which is a measure
of change over time that takes into account the variability within
the sample at baseline. RESULTS: At 1 year, patients adminis-
tered rimonabant 20 mg once daily (N = 339) reported signiﬁ-
cantly greater improvement (p < 0.001, and p = 0.03 for Work)
in IWQOL-Lite total score and 3 out of 5 domains (Physical
Function, Self-esteem and Work) than patients in the placebo
group (N = 348) (no signiﬁcant change in Sexual Life and Public
Distress). These improvements were clinically meaningful (ES >
0.2). Also, there was a trend to fewer days missed from work
reported by patients on rimonabant 20 mg (720 days) compared
with those on placebo (1242 days) over the study period (p =
0.2 based on the number of patients with at least 1 day missed
from work). CONCLUSIONS: HRQOL results showed both a
statistically signiﬁcant and clinically meaningful improvement in
total score and also several domains (Physical Function, Self-
esteem and Work) of the IWQOL-Lite questionnaire, with
rimonabant versus placebo after a once daily administration of
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OBJECTIVES: To assess the efﬁcacy of a new, ready-to-use intra-
venous paracetamol in postoperative pain management in com-
parison with placebo, oral paracetamol, propacetamol and other
NSAIDs. METHODS: Electronic databases search (Medline—
PubMED, EMBASE, Cochrane Database of Systematic Reviews,
Cochrane Central Register of Controlled Trials, Core Biomedical
Collection), until March 2006, was conducted for randomised
controlled trials on postoperative pain management with intra-
venous paracetamol in monotherapy or in combined treatment.
Only full text articles published in peer-reviewed journals were
accepted. Study results were combined in meta-analysis plots
using RevMan, where appropriate. RESULTS: Six studies met the
inclusion criteria: four compared intravenous paracetamol with
placebo, one with oral paracetamol, two with propacetamol and
one with metamizole. All studies were methodologically of high
quality (average 4.83 points in Jadad scale). Treatment with intra-
venous paracetamol was signiﬁcantly superior to placebo in pain
relief, pain intensity difference, reduction of opioid consumption
and patient treatment satisfaction (by 22% to 325%). Patients
treated with intravenous paracetamol received less opioids than
treated with oral paracetamol, whereas incidence of postopera-
tive nausea and vomiting did not differ. No signiﬁcant difference
was obtained between intravenous paracetamol and propaceta-
